EUVIMEDEUVIMED entdecken
Crossref

1747-P: Hospitalizations and Outcomes in Adults with Type 2 Diabetes (T2D) Treated with Weekly Insulin Efsitora Alfa (Efsitora): Results from the QWINT Program

ATHENA PHILIS-TSIMIKAS, RODOLFO J. GALINDO, BRUNO GUERCI, DAVIDA KRUGER, REBECCA THRELKELD, BELLINA MUSHALA, ESTHER M. LEVASSEUR, SHYAM CP, ANDREA GOLDYN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1747-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ATHENA PHILIS-TSIMIKAS und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: QWINT 1-4 were phase 3 trials assessing the efficacy and safety of efsitora, an innovative once-weekly basal insulin for treatment of T2D, compared to daily basal insulin. This post hoc analysis examined hospitalizations and outcomes of QWINT participants.

Methods

Adults with T2D (QWINT-1-4; efsitora N=1883, comparator N=1556) were randomized to efsitora or comparators (degludec or glargine). Participants with hospitalizations for any reason were analyzed for incidence, length of stay (LOS), trial completion, and hypoglycemia rates.

Results

The hospitalization incidence and LOS were similar between groups (9.2% [n: 173] vs. 7.1% [n: 110] and a median of 5.0 days vs. 5.0 days) in efsitora vs. comparators. Most participants with hospitalizations completed the trial treatment (73.4% vs. 83.6%). Clinically significant hypoglycemia reported before and after hospitalization was similar between the pooled efsitora and comparator groups (Figure). Data for hypoglycemia during hospitalization is not included due to differences in reporting methods and limited availability.

Conclusion

Participants treated with efsitora had similar incidence of hospitalizations, with limited impact on hypoglycemia rates or trial discontinuation compared to daily basal comparators. Disclosure A. Philis-Tsimikas: Research Support; Current; Dexcom, Inc., Lilly, Novo Nordisk. Advisory Panel; Current; Novo Nordisk, Gan & Lee Pharmaceuticals. Research Support; Current; Sanofi-Aventis U.S. R.J. Galindo: Consultant; Ended; Abbott, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Novo Nordisk, Medtronic. Research Support; Current; Roche Pharmaceuticals, Boehringer Ingelheim International GmbH, Novo Nordisk. B. Guerci: Other - member of the EASD; Current; European Association for the Study of Diabetes. Consultant; Current; Eli Lilly and Company. Advisory Panel; Current; Novo Nordisk. Board Member; Current; Dexcom, Inc. Advisory Panel; Current; Medtronic. Research Support; Current; Insulet Corporation. Consultant; Current; AstraZeneca. Board Member; Current; Ypsomed AG, Pfizer Inc. Consultant; Current; Abbott. Advisory Panel; Current; Sanofi. D. Kruger: Advisory Panel; Current; Abbott Diabetes. Speaker's Bureau; Current; Abbott. Advisory Panel; Current; Dexcom, Inc. Speaker's Bureau; Current; Dexcom, Inc. Research Support; Current; Abbott Diabetes. Advisory Panel; Current; Eli Lilly and Company. Speaker's Bureau; Current; Eli Lilly and Company. Advisory Panel; Current; Novo Nordisk. Speaker's Bureau; Current; Novo Nordisk. Research Support; Current; Insulet Corporation. Advisory Panel; Current; MannKind Corporation, Medtronic, Provention Bio, Inc., CeQur SA, Corcept Therapeutics. Speaker's Bureau; Current; CeQur SA, Corcept Therapeutics. Research Support; Current; Abbott Diabetes. Speaker's Bureau; Current; Sanofi. Advisory Panel; Current; Tandem Diabetes Care, Inc. Speaker's Bureau; Current; Tandem Diabetes Care, Inc. Research Support; Current; Tandem Diabetes Care, Inc. Advisory Panel; Current; Insulet Corporation. Speaker's Bureau; Current; Insulet Corporation. Consultant; Current; Sequel. Speaker's Bureau; Current; sequel. Research Support; Current; sequel. R. Threlkeld: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. B. Mushala: None. E.M. Levasseur: None. S. Cp: None. A. Goldyn: None.

Zitieren

APA

PHILIS-TSIMIKAS, A., GALINDO, R. J., GUERCI, B., KRUGER, D., THRELKELD, R., MUSHALA, B., LEVASSEUR, E. M., CP, S., & GOLDYN, A. (2026). 1747-P: Hospitalizations and Outcomes in Adults with Type 2 Diabetes (T2D) Treated with Weekly Insulin Efsitora Alfa (Efsitora): Results from the QWINT Program. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1747-p

Vancouver

PHILIS-TSIMIKAS A, GALINDO RJ, GUERCI B, KRUGER D, THRELKELD R, MUSHALA B, et al. 1747-P: Hospitalizations and Outcomes in Adults with Type 2 Diabetes (T2D) Treated with Weekly Insulin Efsitora Alfa (Efsitora): Results from the QWINT Program. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1747-p

BibTeX
@article{PHILISTSIMIKAS2026,
  author = {PHILIS-TSIMIKAS, ATHENA and GALINDO, RODOLFO J. and GUERCI, BRUNO and KRUGER, DAVIDA and THRELKELD, REBECCA and MUSHALA, BELLINA and LEVASSEUR, ESTHER M. and CP, SHYAM and GOLDYN, ANDREA},
  title = {1747-P: Hospitalizations and Outcomes in Adults with Type 2 Diabetes (T2D) Treated with Weekly Insulin Efsitora Alfa (Efsitora): Results from the QWINT Program},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1747-p}
}
Kostenlos starten →